Kite, a Gilead Company , and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which ...
A new study by Phoenix's Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback